

- [0367] <sup>xvii</sup> Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., Lijnen, H. J. (1998) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas, *Cancer* 62, 531-533.
- [0368] <sup>xviii</sup> Herszenyi, L., Plebani, M., Carraro, P., de Paoli, M., Roveroni, G., Cardin, R., Tulassay, Z., Naccarato, R., Farinati, F. (1999) The role of cysteine and serine proteases in colorectal carcinoma, *Cancer* 86, 1135-1142.
- [0369] <sup>xix</sup> Harvey, S. R., Hurd, T. C., Markus, G., Martinick, M. I., Penetrante, R. M., Tan, D., Venkataraman, P., DeSouza, N., Sait, S. N. J., Driscoll, D. L., Gibbs, J. F. (2003) Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9 and von Willebrand factor in pancreatic cancer, *Clin. Cancer Res.* 9, 4935-4943.
- [0370] <sup>xx</sup> Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., Pegram, M. (2001) Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer, *Clin. Cancer Res.* 7, 1743-1749.
- [0371] <sup>xxi</sup> Schmitt, M., Wilhelm, O. G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E., Graeff, H., Gänzbacher, B., Kessier, H., Bürgle, M., Stürzebecher, J., Sperl, S., Magdolen, V. (2000) The urokinase-type plasminogen activator system as a novel target for tumor therapy, *Fibrinolysis & Proteolysis* 14, 114-132.
- [0372] <sup>xxii</sup> Ertongur, S., Lang, S., Mack, B., Wosikowski, K., Muehlenweg, B., Gires, O. (2004)
- [0373] Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system, *Int. J. Cancer* 2004, 110, 815-824.
- [0374] <sup>xxiii</sup> Ossowski, L., Reich, E. (1983) Antibodies to plasminogen activator inhibit human tumor metastasis, *Cell* 35, 611-619.
- [0375] <sup>xxiv</sup> Liu, S., Aaronson, H., Mitola, D. J., Leppla, S. H., Bugge, T. H. (2003) Potent antitumor activity of a urokinase-activated engineered anthrax toxin, *Proc. Natl. Acad. Sci. U.S.A.* 100, 657-662.
- [0376] <sup>xxv</sup> Min, H. Y., Doyle, L., V., Vitt, C. R., Zandomella, C. L., Stratton-Thomas, J. R., Shuman, M. A., Rosenberg, S. (1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice, *Cancer Res.* 56, 2428-2433.
- [0377] <sup>xxvi</sup> Vallera, D. A., Li, C., Jin, N., Mortari-Panoskatis, A., Hall, W. A. (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT, *J. Natl. Cancer Inst.* 94, 597-606.
- [0378] <sup>xxvii</sup> Spiegel, D. A. (2010) Synthetic immunology to engineer human immunity, *Nat. Chem. Biol.* 6, 871-872.
- [0379] <sup>xxviii</sup> Murelli, R. P., Zhang, A. X., Michel, J., Jorgensen, W. L., Spiegel, D. A. (2009) Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer, *J. Am. Chem. Soc.* 131, 17090-17092.
- [0380] <sup>xxix</sup> Lu, Y., Low, P. S. (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors, *Cancer Immunol. Immunother.* 51, 153-162.
- [0381] <sup>xxx</sup> Lu, Y., Segal, E., Lown, P. S. (2005) Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells, *Int. J. Cancer* 116, 710-719.
- [0382] <sup>xxxi</sup> Popkov, M., Gonzalez, B., Sinha, S. C., Barbas, C. F., III. (2009) Instant immunity through chemically programmable vaccination and covalent self-assembly *Proc. Natl. Acad. Sci. U.S.A.* 106, 4378-4383.
- [0383] <sup>xxxii</sup> Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., Kiessling, L. L. (2007) Selective tumor cell targeting using low-affinity, multivalent interactions, *ACS Chem. Biol.* 2, 119-127.
- [0384] <sup>xxxiii</sup> Ortega, E., Kostovetzky, M., Larralde, C. (1984) Natural DNP-binding immunoglobulins and antibody multispecificity, *Mol. Immunol.* 21, 883-888.
- [0385] <sup>xxxiv</sup> Kettner, C., Shaw, E. (1981) Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone, *Methods Enzymol.* 80, 826-842.
- [0386] <sup>xxxv</sup> Spraggon, G., Phillips, C., Nowak, U. K., Ponting, C. P., Saunders, D., Dobson, C. M., Stuart, D. I., Jones, E. Y. (1995) The crystal structure of the catalytic domain of human urokinase-type plasminogen activator, *Structure* 3, 681-691.
- [0387] <sup>xxxvi</sup> Williams, E. B., Krishnaswamy, S., Mann, K. G. (1989) Zymogen/enzyme discrimination using peptide chloromethyl ketones, *J. Biol. Chem.* 264, 7536-7545.
- [0388] <sup>xxxvii</sup> Walker, B., Elmore, D. T. (1984) The behaviour of urokinase and porcine kidney cell plasminogen activator towards some synthetic peptides *Thromb. Res.* 34, 103-107.
- [0389] <sup>xxxviii</sup> Binnema, D. J., van Iersel, J. J. L., Dooijewaard, G. (1986) Quantitation of urokinase antigen in plasma and culture media by use of an ELISA, *Thromb. Res.* 43, 569-577.
- [0390] <sup>xxxix</sup> Rajagopal, V., Kreitman, R. J. (2000) Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the  $\alpha_2$ -macroglobulin receptor, *J. Biol. Chem.* 275, 7566-7573.
- [0391] <sup>xl</sup> Bracher, M., Gould, H. J., Sutton, B. J., Domrowsicz, D., Karagiannis, S. N. (2007) Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis, *J. Immunol. Methods* 323, 160-171.
- [0392] <sup>xli</sup> Boltz-Nitulescu, G., Willheim, M., Spittler, A., Leutmezer, F., Tempfer, C., Winkler, S. (1995) Modulation of IgA, IgE, and IgG Fc receptor expression of human mononuclear phagocytes by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and cytokines, *J. Leuko. Biol.* 58, 256-262.
- [0393] <sup>xlii</sup> Lu, Yingjuan, Klein, P. J., Westrick, E., Xu, L.-C., Santhapuram, H. K. R., Bloomfield, A., Howard, S. J., Vlahov, I. R., Ellis, P. R., Low, P. S., Leamon, C. P. (2009) Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer, *AAPSJ* 2, 628-638.
- [0394] <sup>xliii</sup> Kute, T. E., Savage, L., Stehle, J. R. Jr., Kim-Shapiro, J. W., Blanks, M. J., Wood, J., Vaughn, J. P. (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing, *Cancer Immunol. Immunother.* 58, 1887-1896.
- [0395] <sup>xliv</sup> Zhu, J., Wang, X., Xu, X., Abassi, Y. A. (2006) Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays, *J. Immunol. Methods* 309, 25-33.
- [0396] <sup>xlv</sup> Weiner, G. J. (2007) Monoclonal antibody mechanisms of action in cancer, *Immunol. Res.* 39, 271-278.